Today's Stock Analyst Downgrades

Company	Action	Brokerage	Analyst	Current Price	Price Target	Rating
ABVX Abivax	Downgraded by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Faisal Khurshid Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$72.50 -44.1%	$160.00 ➝ $90.00	Buy ➝ Hold
FULC Fulcrum Therapeutics	Downgraded by	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Edward Tenthoff Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$3.14 -51.1%	$3.00	Overweight ➝ Neutral
FULC Fulcrum Therapeutics	Downgraded by	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrew S. Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$3.14 -51.1%	$3.00	Buy ➝ Neutral
FULC Fulcrum Therapeutics	Downgraded by	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	James Condulis Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$3.14 -51.1%	$3.00	Buy ➝ Hold
FULC Fulcrum Therapeutics	Downgraded by	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Schwartz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$3.14 -51.1%	$4.00	Outperform ➝ Market Perform
FULC Fulcrum Therapeutics	Downgraded by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$3.14 -51.1%		Underperform ➝ Underweight
HRTX Heron Therapeutics	Downgraded by	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$0.45 -45.6%		Buy ➝ Hold
INTU Intuit	Downgraded by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kash Rangan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$322.14 -8.9%	$519.00 ➝ $276.00	Neutral ➝ Sell
META Meta Platforms	Downgraded by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$597.63 -0.5%		Buy ➝ Sell
META Meta Platforms	Downgraded by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Stephen Ju Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$597.63 -0.5%		Buy ➝ Neutral
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
OKTA Okta	Downgraded by	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gregg Moskowitz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$135.32 -3.2%	$110.00 ➝ $125.00	Outperform ➝ Neutral
SARO StandardAero	Downgraded by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sheila Kahyaoglu Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$25.17 -8.0%	$34.00 ➝ $30.00	Buy ➝ Hold
SFTBY SoftBank Group	Downgraded by	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$27.38 -4.5%		Buy ➝ Hold
SGBAF SES	Downgraded by	New Street Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$10.35 -3.7%		Neutral ➝ Sell
SHW Sherwin-Williams	Downgraded by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joshua Spector Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$292.65 -0.8%	$385.00 ➝ $330.00	Buy ➝ Neutral
SQM Sociedad Quimica y Minera	Downgraded by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lucas Ferreira Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$80.71 -3.2%	$94.00 ➝ $100.00	Overweight ➝ Neutral
TMHC Taylor Morrison Home	Downgraded by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Dahl Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$71.51 -0.1%	$69.00 ➝ $72.50	Outperform ➝ Sector Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 12:02 AM ET.

Frequently Asked Questions

Analyst ratings are the "buy" and "sell" labels, plus price targets, that investment researchers attach to specific securities. These ratings are based on financial data, earnings reports and conversations with company executives.

Analyst ratings provide plenty of helpful information, but you shouldn't use an analyst's "buy" rating as the sole reason you purchase a security. Analysts aren't immune to conflicts of interest or outside parties' influence, so ensure you always understand why a stock was labeled a "buy" or "sell."

Ratings give investors the analyst's overall opinion about a particular stock and price targets based on the company's valuation and prospects. Analysts often attend conference calls, ask questions and provide in-depth information about companies that are difficult to acquire elsewhere.

Stock Analyst Downgrades

Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Stock Analyst Downgrades

Frequently Asked Questions

What are analyst ratings?

Should you trust analyst ratings?

What does an analyst rating tell you about a stock?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools